|I am an Instructor in Medicine at the Harvard Medical School, Boston, MA, in the laboratory of Dr. Irene Ghobrial in the department of Medical Oncology at the Dana-Farber Cancer Institute. I also hold an appointment as Visiting Professor in the laboratory of Dr. Jeremiah Johnson, Department of Chemistry, Massachusetts Institute of Technology.
My main research focus lies around my clinical formation as Medical Physicist (French ABR) in imaging and my PhD in nanomedicine from the University of Lyon, France under the supervision of Prof. Olivier Tillement. Since then my research focus mostly on the development of novel diagnostic imaging biomarkers, drug delivery methods, and combined approaches also known as theranostic.
In 2017, I obtained my PhD degree in the field of nanomedicine at the University of Lyon, France under the supervision of Prof. Olivier Tillement in collaboration with Dr. Ross Berbeco’s team in the department of radiation oncology of the Dana-Farber Cancer Institute/Brigham and Women’s Hospital/Harvard Medical School where I performed my research. This research was at the intersection of biotechnology and radiation therapy. More specifically, I have been working on the development of a novel theranostic gadolinium-based nanoparticle developed for MRI-guided radiation therapy for different cancer treatments, such as pancreatic adenocarcinoma. My team demonstrated the nanoparticles potential at a preclinical level with small and large animal studies and is currently under evaluation for a Phase I clinical trial (NCT02820454, NCT03308604).
Since the end of 2016, I joined the lab of Dr. Irene M. Ghobrial in the department of Medical Oncology at the Dana-Farber Cancer Institute/Harvard Medical School and in the lab of Dr. Peter P. Ghoroghchian at the David H Koch Institute for Integrative Cancer Research at MIT to develop new theranostic approaches for Multiple Myeloma and Ovarian cancer, including imaging biomarkers and new therapeutic solutions.
Since January 2018, I joined the lab of Dr. Jeremiah Johnson as Visiting Professor to pursue the development of drug delivery specifically targeted to the malignant plasma cells for Multiple Myeloma.
For more information, please click on the following: